Literature DB >> 8758556

Lack of activity of artemether for prophylaxis and treatment of Toxoplasma gondii and Pneumocystis carinii infections in rat.

M Brun-Pascaud1, F Chau, F Derouin, P M Girard.   

Abstract

Artemisinin and its derivatives have been found effective in vivo against Plasmodium and in vitro against Toxoplasma gondii and Pneumocystis carinii. We tested the activity of artemether for prophylaxis and treatment in the rat model of concurrent T. gondii and P. carinii infection. Artemether at doses of 18 and 100 mg/kg administered (s.c.) in prophylaxis did not prevent toxoplasmosis or pneumocystosis, while trimethoprimsulfamethoxazole (reference treatment) was effective for prevention of both infections. Similar results were obtained in curative studies. These results do not support the use of artemether for prevention or treatment of toxoplasmosis or pneumocystosis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8758556     DOI: 10.1051/parasite/1996032187

Source DB:  PubMed          Journal:  Parasite        ISSN: 1252-607X            Impact factor:   3.000


  4 in total

1.  Artemisone and artemiside control acute and reactivated toxoplasmosis in a murine model.

Authors:  Ildiko R Dunay; Wing Chi Chan; Richard K Haynes; L David Sibley
Journal:  Antimicrob Agents Chemother       Date:  2009-07-27       Impact factor: 5.191

2.  Artemisinin-resistant mutants of Toxoplasma gondii have altered calcium homeostasis.

Authors:  Kisaburo Nagamune; Silvia N J Moreno; L David Sibley
Journal:  Antimicrob Agents Chemother       Date:  2007-08-13       Impact factor: 5.191

Review 3.  Artemisinins: their growing importance in medicine.

Authors:  Sanjeev Krishna; Leyla Bustamante; Richard K Haynes; Henry M Staines
Journal:  Trends Pharmacol Sci       Date:  2008-08-25       Impact factor: 14.819

4.  Apoptotic activity and anti-Toxoplasma effects of artemether on the tachyzoites and experimental infected Vero and J774 cell lines by Toxoplasma gondii.

Authors:  Hajar Mikaeiloo; Fatemeh Ghaffarifar; Abdolhossein Dalimi; Zohreh Sharifi; Zuhair Mohammad Hassan
Journal:  Indian J Pharmacol       Date:  2016 Mar-Apr       Impact factor: 1.200

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.